Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
NCT02004262
Completed
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2018
Locations: Scottsdale Healthcare Research Institute, Scottsdale, Arizona +20 locations
Conditions: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Register for Updates
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
NCT01414855
Completed
This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab \[RO5072759 (GA101)\] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2018
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Lymphoma, B-Cell
Register for Updates
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01341301
Completed
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for patients who have evidence of their disease at the time of transplant. In this research study, a way of strengthening the response of the donor cells against the disease has been developed. Patients will undergo one additional day between the two steps of the transplant which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2018
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Hematologic Malignancy
Register for Updates
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
NCT00669877
Completed
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma. Another goal is to see how well this treatment works when given with Rituximab. The safety of the combined treatment will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
04/18/2018
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Register for Updates
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
NCT01417000
Completed
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2018
Locations: H. Lee Moffitt Cancer Center, Tampa, Florida +9 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
NCT00794820
Completed
Primary Objective: * To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL. Secondary Objective: * To evaluate remission duration and survival.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/05/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
NCT00001426
Completed
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/04/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Ovarian Neoplasm
Register for Updates
Carbohydrate-Protein Supplementation During Endurance Running
NCT00972387
Completed
The purpose of this study is to assess whether the greater performance benefits from ingesting carbohydrate-protein supplements during endurance running, in comparison to the traditionally used carbohydrate supplement, is attributed to the extra calories contained in the carbohydrate-protein supplement or the presence of protein.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
04/03/2018
Locations: Health Physical Education and Recreation Building, Knoxville, Tennessee
Conditions: Supplementation During Endurance Performance
Register for Updates
Fasting on Newly Diagnosed Breast Cancer
NCT02379585
Terminated
This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2018
Locations: Western Regional Medical Center, Goodyear, Arizona
Conditions: HER2-positive Breast Cancer
Register for Updates
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
NCT00626626
Terminated
Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporation into a regimen for pre-transplant conditioning of acute leukemia and lymphoma patients is logical, exploiting both the anti-tumor activities it is recognized to have and the immunosuppressive activi... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/23/2018
Locations: Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
Register for Updates
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047
Completed
The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/21/2018
Locations: Hays Medical Center, Hays, Kansas +1 locations
Conditions: Breast Cancer
Register for Updates
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
NCT00004474
Completed
OBJECTIVES: I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin as a conditioning regimen.
Gender:
ALL
Ages:
59 years and below
Trial Updated:
03/09/2018
Locations: Roswell Park Cancer Institute, Buffalo, New York +3 locations
Conditions: Aplastic Anemia
Register for Updates